Vimarsana
Biggest News Aggregation in the World

Pharma Equity Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Equity Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Equity Group Today - Breaking & Trending Today

Pharma Equity A/S : 2024 Q1 Consolidated Interim Report - Vimarsana News

Pharma Equity A/S : 2024 Q1 Consolidated Interim Report

Consolidated interim report for the 3 month-period ended 31 March 2024 Pharma Equity Group A/S Slotsmarken 18, 2.,...

The Board of Director's decision to issue convertible - Vimarsana News

The Board of Director's decision to issue convertible

     The Board of Director's decision to issue convertible loans   16 May 2024Company Announcement no. 18   The Board of Directors of Pharma Equity Group...

The Board of Director's decision to issue convertible loans - Vimarsana News

The Board of Director's decision to issue convertible loans

     The Board of Director's decision to issue convertible loans ...

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company's patented drug candidate RNX-051. -April 05, 2024 at 05:23 am EDT - Vimarsana News

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company's patented drug candidate RNX-051. -April 05, 2024 at 05:23 am EDT

5 April 2024 Company Announcement No. 11 Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s...

Pharma Equity A/S : Group's subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company's patented drug candidate RNX-051. -April 05, 2024 at 05:29 am EDT - Vimarsana News

Pharma Equity A/S : Group's subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company's patented drug candidate RNX-051. -April 05, 2024 at 05:29 am EDT

Danish English ...